Boston University
Synthetic and electrochemical strategies for the preparation of modified nucleotides and anticancer small molecules
Abstract
dc:description.abstractA class of small molecule inhibitors of oncogenic transcription factor LSF were developed. These “Factor Quinolinone Inhibitors”, or FQIs, were optimized through SAR development to maximize potency. An asymmetric Friedel-Crafts reaction was developed to afford (S)-FQI-34, the more active enantiomer of chiral racemic candidate FQI-34. Many factors were considered in the eventual selection of lead achiral compound FQI 2-34. Considerations included its general balance of efficacy, robustness, and ease of synthesis, as well as its clinical success in vivo. Ultimately, the struggle to achieve high enantioselectivity in (S)-FQI-34 synthesis led to redirection, but future asymmetric synthesis efforts are proposed. RNA therapeutics have revolutionized modern medicine as seen with mRNA COVID-19 vaccines. However, challenges associated with mRNA include adverse immune effects and large/frequent doses. saRNA (self-amplifying RNA) is a potential alternative, but clinical success has been limited as wild type saRNA evokes a strong interferon response. However, a screen identified several modified nucleotides that, when incorporated into saRNA, increase protein expression and suppress interferon response. To expand the library of modified nucleotides, a series of fluorinated nucleotides were synthesized, as fluorine is known to induce unique pharmacological effects in small molecule drugs. Synthetic routes were developed and adjusted for various nucleoside derivatives. Modified nucleotides were successfully incorporated into saRNA and a range of mCherry reporter protein expression was observed upon cell transfection of constructs, revealing potential trends between nucleotide modification and RNA-dependent RNA polymerase activity. Of various synthetic techniques, electrochemistry was explored to install fluorinated groups on uracil, the synthetic precursor to uridines/cytidines. In addition to RNA therapeutics, purines and pyrimidines as well as fluorinated moieties are extremely prevalent in small molecule drug development. Under constant current in an undivided cell with the IKA Electrasyn 2.0, difluoromethylation and trifluoromethylation of uracil was achieved and the scope was expanded to an array of purines and pyrimidines in up to 80% yield. The method features mild conditions, operational simplicity, and reusable electrodes. Yield limitations were studied in an electronics-based framework and mitigated through implementation of a microflow electrolysis platform. Adapting the difluoromethylation protocol to flow significantly improved the reaction’s throughput/scalability and volume-time output.
Degree
thesis:*- Name thesis:degree_name
- Doctor of Philosophy
- Level thesis:degree_level
- doctoral
- Discipline thesis:degree_discipline
- Chemistry
- Grantor
- Boston University
- Year dc:date.issued
- 2026
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Corazzata, Kaitlyn
- Advisor dc:contributor.advisor
-
- Schaus, Scott E
- ORCID dc:identifier.orcid
Subjects
dc:subject × 2Rights
- Language dc:language.iso
- en_US
Identifiers
dc:identifier.*- Handle dc:identifier.uri
- https://hdl.handle.net/2144/53621